Anticancer Efficacy of KRAS(G12C) Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRAS(G12C)-Mutant Pancreatic and Lung Cancers

KRAS(G12C) inhibitors, such as sotorasib and adagrasib, have revolutionized cancer treatment for patients with KRAS(G12C)-mutant tumors. However, patients receiving these agents as monotherapy often develop drug resistance. To address this issue, we evaluated the combination of the PAK4 inhibitor KP...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Husain Yar, Nagasaka, Misako, Aboukameel, Amro, Alkhalili, Osama, Uddin, Md. Hafiz, Bannoura, Sahar F., Mzannar, Yousef, Azar, Ibrahim, Beal, Eliza W., Tobon, Miguel E., Kim, Steve H., Beydoun, Rafic, Baloglu, Erkan, Senapedis, William, El-Rayes, Bassel F., Philip, Philip A., Mohammad, Ramzi M., Shields, Anthony F., Al Hallak, Mohammed Najeeb, Azmi, Asfar S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Small Molecule Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690049/
https://www.ncbi.nlm.nih.gov/pubmed/37703579
http://dx.doi.org/10.1158/1535-7163.MCT-23-0251

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690049/
https://www.ncbi.nlm.nih.gov/pubmed/37703579
http://dx.doi.org/10.1158/1535-7163.MCT-23-0251

Ejemplares similares